- List
- By Topic
- On Map
- Search Details

Neoplastic Syndromes, Hereditary | "neurofibromatosis type 2" OR "neurofibromatosis"
Need help? See RSS Feeds
Choose a feed type:

Neoplastic Syndromes, Hereditary | "neurofibromatosis type 2" OR "neurofibromatosis" (147 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02934256 | Recruiting | Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
20 | All | 16 Years to 50 Years (Child, Adult) | NCT02934256 | Tian-drug-neuro002 | Icotinib | July 2016 | January 2018 | June 2018 | October 14, 2016 | February 9, 2017 |
|
|
2 | NCT02104323 | Completed | Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
20 | All | 16 Years to 30 Years (Child, Adult) | NCT02104323 | Tian-drug-neuro001 ChiCTR-ONRC-14004210 |
Endostatin | January 2014 | April 2016 | April 2016 | April 4, 2014 | February 9, 2017 |
|
|
3 | NCT00911248 | Suspended | PTC299 for Treatment of Neurofibromatosis Type 2 |
|
|
Interventional | Phase 2 |
|
Industry / U.S. Fed |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT00911248 | PTC299-ONC-007-NF2 NF080100 |
July 2009 | May 2012 | May 2012 | June 1, 2009 | April 9, 2012 |
|
||
4 | NCT02129647 | Recruiting | Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
|
|
Interventional | Phase 2 |
|
Other |
|
|
17 | All | 18 Years and older (Adult, Senior) | NCT02129647 | 14-00004 | April 2014 | January 2019 | January 2019 | May 2, 2014 | March 29, 2018 |
|
||
5 | NCT01419639 | Completed Has Results |
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
10 | All | 3 Years and older (Child, Adult, Senior) | NCT01419639 | RAD001 NF2 (11-00587) 2010-10-011 |
October 2011 | December 2012 | December 2013 | August 18, 2011 | July 18, 2017 | August 7, 2015 |
|
|
6 | NCT00973739 | Completed Has Results |
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
21 | All | 4 Years to 80 Years (Child, Adult, Senior) | NCT00973739 | 09-0328 | September 2009 | October 2012 | November 2012 | September 9, 2009 | March 22, 2016 | March 22, 2016 |
|
|
7 | NCT01207687 | Completed Has Results |
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
14 | All | 12 Years and older (Child, Adult, Senior) | NCT01207687 | NCI-2012-02987 J1002 NA_00034732 8248 P30CA006973 |
October 2010 | February 2013 | March 2014 | September 23, 2010 | December 21, 2017 | August 17, 2017 |
|
|
8 | NCT01490476 | Completed | Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients |
|
|
Interventional | Phase 2 |
|
Other |
|
|
10 | All | 15 Years and older (Child, Adult, Senior) | NCT01490476 | P101202 2011-002228-42 |
AFINF2 | January 2012 | April 2016 | January 2017 | December 13, 2011 | May 23, 2017 |
|
|
9 | NCT00030043 | Completed | An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors |
|
|
Interventional | Phase 1 |
|
U.S. Fed |
|
10 | All | 18 Years and older (Adult, Senior) | NCT00030043 | FD-R-001969-01 | September 2001 | August 2003 | January 31, 2002 | March 25, 2015 |
|
||||
10 | NCT01345136 | Active, not recruiting | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
4 | All | 16 Years to 65 Years (Child, Adult) | NCT01345136 | 13-001492 | July 1, 2015 | February 1, 2019 | February 1, 2020 | April 29, 2011 | February 21, 2018 |
|
||
11 | NCT03359304 | Not yet recruiting | The Neurofibromatosis-associated Tumor Biobank |
|
Observational |
|
Other |
|
|
300 | All | Child, Adult, Senior | NCT03359304 | PKU-MPNST | March 1, 2018 | March 1, 2023 | March 1, 2028 | December 2, 2017 | December 2, 2017 | |||||
12 | NCT02831257 | Active, not recruiting | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas |
|
|
Interventional | Phase 2 |
|
Other / Industry / U.S. Fed |
|
|
18 | All | 18 Years and older (Adult, Senior) | NCT02831257 | 15-590 | August 31, 2016 | March 2020 | November 2024 | July 13, 2016 | September 28, 2017 |
|
||
13 | NCT02811718 | Recruiting | Resiliency Training for Patients With NF2 Via Videoconferencing With Skype |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02811718 | 2013P002605b | July 2016 | June 2018 | June 2018 | June 23, 2016 | April 4, 2017 |
|
||
14 | NCT01767792 | Active, not recruiting | Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
22 | All | 6 Years and older (Child, Adult, Senior) | NCT01767792 | AVF4807 W81XWH-12-1-0155 |
May 2013 | December 2018 | December 2019 | January 14, 2013 | May 4, 2017 |
|
||
15 | NCT00352599 | Completed | Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) |
|
|
Interventional | Phase 1 |
|
Other |
|
|
44 | All | 10 Years to 50 Years (Child, Adult) | NCT00352599 | 05-08-069-01 | NF1 | September 2009 | March 2014 | March 2014 | July 14, 2006 | November 22, 2016 |
|
|
16 | NCT01885767 | Recruiting | Neurofibromatosis (NF) Registry Portal |
|
Observational |
|
Other |
|
|
10000 | All | Child, Adult, Senior | NCT01885767 | CTF001 | June 2012 | June 2022 | June 2050 | June 25, 2013 | January 25, 2018 |
|
||||
17 | NCT02589912 | No longer available | Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients |
|
|
Expanded Access |
|
Other | All | 12 Years to 80 Years (Child, Adult, Senior) | NCT02589912 | 15-113H | October 28, 2015 | December 6, 2016 |
|
|||||||||
18 | NCT03050268 | Recruiting | Familial Investigations of Childhood Cancer Predisposition |
|
Observational |
|
Other |
|
|
3000 | All | Child, Adult, Senior | NCT03050268 | SJFAMILY | SJFAMILY | April 6, 2017 | March 31, 2037 | March 31, 2037 | February 10, 2017 | January 5, 2018 |
|
|||
19 | NCT03095248 | Recruiting | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
34 | All | 3 Years to 45 Years (Child, Adult) | NCT03095248 | SEL-TH-1601 2016-8833 |
SEL-TH-1601 | May 8, 2017 | May 2020 | May 2021 | March 29, 2017 | May 11, 2017 |
|
|
20 | NCT00754780 | Completed | Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 |
|
|
Interventional | Phase 2 |
|
Other |
|
|
24 | All | 18 Years to 70 Years (Adult, Senior) | NCT00754780 | 1835-99 MC0077 Mayo Pirfenidone Study |
September 2000 | August 2004 | September 18, 2008 | March 19, 2012 | ||||
21 | NCT02246231 | Unknown † | Effect of Implant Position on Magnetic Resonance Image Distortion |
|
|
Interventional | Not Applicable |
|
Other |
|
|
12 | All | 18 Years and older (Adult, Senior) | NCT02246231 | R01623 | November 2011 | January 2015 | January 2015 | September 22, 2014 | September 22, 2014 |
|
||
22 | NCT01218139 | Unknown † | Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients |
|
Observational |
|
Other |
|
50 | All | Child, Adult, Senior | NCT01218139 | LEGIUS_001 | September 2007 | September 2010 | December 2010 | October 11, 2010 | October 11, 2010 |
|
|||||
23 | NCT00004437 | Completed | Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 |
|
|
Interventional | Phase 2 |
|
U.S. Fed / Industry |
|
All | 12 Years and older (Child, Adult, Senior) | NCT00004437 | 199/13400 CC-FDR001283 |
October 1999 | October 2000 | October 19, 1999 | March 25, 2015 | ||||||
24 | NCT02680431 | Enrolling by invitation | Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 |
|
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 85 Years (Adult, Senior) | NCT02680431 | 141-1801-2015 | January 2016 | December 2020 | December 2020 | February 11, 2016 | February 11, 2016 | ||||
25 | NCT02153931 | Completed | Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 |
|
Observational |
|
NIH |
|
|
33 | All | 18 Years to 99 Years (Adult, Senior) | NCT02153931 | 140113 14-C-0113 |
May 31, 2014 | April 6, 2015 | April 6, 2015 | June 3, 2014 | March 2, 2018 |
|
||||
26 | NCT02728388 | Recruiting | Photodynamic Therapy for Benign Dermal Neurofibromas |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | All | 14 Years to 30 Years (Child, Adult) | NCT02728388 | PRO00026795 | August 2016 | August 2022 | August 2023 | April 5, 2016 | August 14, 2017 |
|
||
27 | NCT01410006 | Completed | Neurofibromatosis Type 1 Patient Registry |
|
Observational |
|
Other |
|
|
2391 | All | Child, Adult, Senior | NCT01410006 | 10-1036 | NPRI | May 2011 | July 2017 | July 2017 | August 4, 2011 | July 25, 2017 |
|
|||
28 | NCT00508235 | Completed | Quality of Friendships in Children With Neurofibromatosis |
|
|
Observational |
|
Other |
|
|
61 | All | 8 Years to 18 Years (Child, Adult) | NCT00508235 | 2004-0791 | December 2004 | July 2009 | July 2009 | July 27, 2007 | August 1, 2012 |
|
|||
29 | NCT03210285 | Not yet recruiting | WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data |
|
|
Observational |
|
Other |
|
|
100 | All | up to 99 Years (Child, Adult, Senior) | NCT03210285 | NF2Tue | NF2 | July 31, 2017 | September 1, 2018 | September 1, 2021 | July 6, 2017 | July 6, 2017 |
|
||
30 | NCT01218152 | Unknown † | Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs |
|
Observational |
|
Other |
|
20 | All | Child, Adult, Senior | NCT01218152 | LEGIUS_002 | October 2010 | June 2011 | December 2011 | October 11, 2010 | October 11, 2010 |
|
|||||
31 | NCT01626846 | Unknown † | How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem |
|
Observational |
|
Other |
|
|
50 | All | 14 Years to 17 Years (Child) | NCT01626846 | NF Survey 2012 | June 2012 | September 2012 | June 25, 2012 | June 25, 2012 |
|
|||||
32 | NCT01650142 | Unknown † | Modifying Genes in Neurofibromatosis 1 |
|
|
Observational |
|
Other |
|
|
450 | All | 18 Years and older (Adult, Senior) | NCT01650142 | AOM 10 005 2010-023137-34 |
NFGENMODIF | May 2012 | September 2015 | September 2015 | July 26, 2012 | June 16, 2014 |
|
||
33 | NCT02387177 | Active, not recruiting | Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype |
|
|
Interventional | Not Applicable |
|
Other |
|
|
55 | All | 12 Years to 17 Years (Child) | NCT02387177 | 2014P000702 | January 2015 | December 2018 | December 2018 | March 12, 2015 | April 4, 2017 |
|
||
34 | NCT02332902 | Completed Has Results |
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T |
|
|
Interventional | Phase 2 |
|
Other |
|
|
24 | All | 18 Years and older (Adult, Senior) | NCT02332902 | HSC-MS-14-0758 | DCLNF1 | February 2015 | March 2016 | March 2016 | January 7, 2015 | June 6, 2017 | June 6, 2017 |
|
35 | NCT00846430 | Unknown † | Medical Treatment of "High-Risk" Neurofibromas |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 2 Years to 30 Years (Child, Adult) | NCT00846430 | 2008-260 | October 2008 | October 2017 | December 2017 | February 18, 2009 | May 21, 2015 |
|
||
36 | NCT00314119 | Completed | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 |
|
Observational |
|
NIH |
|
|
17 | All | 20 Years to 99 Years (Adult, Senior) | NCT00314119 | 060134 06-HG-0134 |
April 10, 2006 | April 12, 2006 | March 29, 2018 |
|
||||||
37 | NCT03310996 | Recruiting | Non-invasive Stimulation in Neurofibromatosis Type 1 |
|
|
Interventional | Not Applicable |
|
Other |
|
|
16 | All | 11 Years to 16 Years (Child) | NCT03310996 | SGIRAS21773 | tDCS is NF1 | October 13, 2017 | June 30, 2018 | June 30, 2018 | October 16, 2017 | October 16, 2017 |
|
|
38 | NCT01673009 | Completed Has Results |
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
|
|
Interventional | Phase 2 |
|
Other |
|
|
36 | All | 3 Years to 65 Years (Child, Adult) | NCT01673009 | 0512-25 | May 2006 | December 2011 | August 2012 | August 27, 2012 | April 6, 2016 | April 6, 2016 |
|
|
39 | NCT00865644 | Completed | Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 |
|
|
Interventional | Phase 1 |
|
Other |
|
|
11 | All | 18 Years and older (Adult, Senior) | NCT00865644 | 08-347 | March 2009 | April 2010 | December 2013 | March 19, 2009 | January 10, 2017 |
|
||
40 | NCT01851135 | Completed | Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 |
|
|
Interventional | Not Applicable |
|
Other |
|
|
286 | All | 8 Years to 59 Years (Child, Adult) | NCT01851135 | RC12_0130 | NF1-QDV | May 2013 | April 2016 | April 2016 | May 10, 2013 | July 6, 2016 |
|
|
41 | NCT00853580 | Completed Has Results |
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
146 | All | 8 Years to 15 Years (Child) | NCT00853580 | X080929007 DOD: W81XWH-05-1 0615 |
STARS | July 2009 | May 2014 | December 2016 | March 2, 2009 | March 12, 2018 | March 12, 2018 |
|
42 | NCT00634270 | Completed Has Results |
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
58 | All | 3 Years to 75 Years (Child, Adult, Senior) | NCT00634270 | F071019012 DOD: W81XWH-05-615. UAB: 251558. |
Protocol 102 | April 2008 | November 2014 | December 2015 | March 13, 2008 | November 17, 2017 | February 14, 2017 |
|
43 | NCT00657202 | Completed | Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
11 | All | 18 Years and older (Adult, Senior) | NCT00657202 | 07-332 | March 2008 | October 2009 | December 2013 | April 14, 2008 | July 7, 2016 |
|
||
44 | NCT02479360 | Completed | Reliability of Functional Outcome Measures in Neurofibromatosis 1 |
|
Observational |
|
Other |
|
|
49 | All | 16 Years and older (Child, Adult, Senior) | NCT02479360 | RJ115/N174 | June 2015 | September 2015 | September 2015 | June 24, 2015 | October 6, 2015 |
|
||||
45 | NCT00598351 | Active, not recruiting | Natural History Study of Patients With Neurofibromatosis Type 2 |
|
Observational |
|
NIH |
|
|
169 | All | 8 Years to 75 Years (Child, Adult, Senior) | NCT00598351 | 080044 08-N-0044 |
January 9, 2008 | January 21, 2008 | April 4, 2018 |
|
||||||
46 | NCT02407405 | Recruiting | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT02407405 | NCI-2015-00456 16-C-0043 B 9840 |
January 11, 2016 | June 30, 2019 | April 3, 2015 | March 19, 2018 |
|
|||
47 | NCT01633008 | Completed | Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain |
|
|
Interventional | Early Phase 1 |
|
NIH |
|
|
28 | All | 12 Years to 99 Years (Child, Adult, Senior) | NCT01633008 | 120155 12-C-0155 |
June 15, 2012 | May 1, 2014 | January 10, 2017 | July 4, 2012 | October 6, 2017 |
|
||
48 | NCT02584413 | Recruiting | Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma |
|
|
Observational |
|
Other |
|
|
80 | All | 1 Year to 7 Years (Child) | NCT02584413 | 201303074 | April 16, 2013 | April 30, 2023 | April 30, 2023 | October 22, 2015 | March 19, 2018 |
|
|||
49 | NCT00667836 | Unknown † | Multi-Center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients |
|
Observational |
|
Other |
|
300 | All | 3 Years to 18 Years (Child, Adult) | NCT00667836 | IRB_00023261 | March 2006 | September 2009 | September 2009 | April 28, 2008 | April 28, 2008 |
|
|||||
50 | NCT02944032 | Recruiting | Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 |
|
|
Interventional | Not Applicable |
|
Other |
|
|
130 | All | 8 Years to 16 Years (Child) | NCT02944032 | 00007343 | COGTRAIN | May 2016 | September 2019 | September 2019 | October 25, 2016 | March 15, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.